HRD-positive and all patients randomized (ITT) Median PFS of 20.2 months for Rubraca vs 9.2 months for placebo in the ITT population The exploratory PFS endpoints were also achieved in both HRD-negative and BRCA mutant subgroups of patients. 今日parp暴涨